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Abstract. Background: The prognostic significance of the
presence of tumour cells in the blood of gastric cancer patients
remains unclear. Their occurrence and its association with the
stage of disease and long-term survival was determined.
Patients and Methods: Fifty-seven patients with stage I-IV
gastric cancer were divided into two groups: these with and
these without circulating tumour cells that were identified as
cytokeratin positive (CK+) cells among CD45– cells (obtained
by sorting of CD45+ leukocytes). Results: Tumour cells were
detected prior surgery in the peripheral blood of 54.4% patients
but no clear association with the stage of disease was observed.
After gastrectomy detection rate was 21.1%. There was no
significant difference in the 5-year survival of patients, with or
without CK+ in the blood. Conclusion: The presence of
circulating tumour cells is of no prognostic value in patients
with resectable gastric cancer. 
The surgical removal of primary tumour and regional lymph
nodes even in early stages of cancer does not prevent the
disease progression (1-6). Over the past decades, both
incidence and mortality rates for gastric cancer have
decreased worldwide. Nevertheless, gastric cancer is still the
second major cause of cancer-related death (2, 4). The
major prognostic factors in gastric cancer are: tumour
staging according to TNM classification, histological type of
tumour according to Lauren, invasion in lymphatic and
vascular system and residual tumour presence (3-8).
Surgical resection is the cornerstone in the treatment of
gastric cancer, but despite the growing number of
potentially curative resections, the rate of tumour
recurrence, both locoregional and distant, is high (3, 6). 
Micrometastases are frequently observed in the lymph
nodes and bone marrow even in less advanced stages of
different types of cancer (9-17). Spread of tumour cells in
gastric cancer occurs via both lymphatic and blood
circulation, and single cancer cells are detected in lymph
nodes and in the blood (9, 14, 16). Moreover, bone marrow,
peritoneal cavity and lymph nodes are the reservoirs of
these cells, which often show no proliferation (10, 14, 15).
The clinical significance and prognostic value of the
presence of cancer micrometastases in bone marrow are still
under discussion, but in pancreatic, colorectal, breast and
gastric cancers it is associated with shortened survival (11,
14, 18). The association between micrometastases in the
bone marrow and impaired survival is observed in gastric
cancer patients (18); however, paradoxically the presence of
tumour cells in the blood just after gastrectomy correlates
with a low rate of tumour recurrence (19). Detection of
circulating tumour cells in the blood after surgery led to the
suggestion that it may facilitate the release of tumour cells
into the blood stream, as in gastric and prostate cancer an
increased frequency of tumour cells in the blood was
observed after surgery (19, 20).
The detection of cancer cells in the blood or bone
marrow requires sensitive methods as the frequency of these
cells is extremely low. Immunocytochemistry, molecular
techniques and immunofluorescence are commonly used for
these studies (14-19, 21-26). The detection of disseminated
cancer cells is generally based on the expression of tumour-
associated markers, e.g. in gastric cancer - TAG72, carcino-
embryonic antigen (CEA) and mucin (MUC), and the
epithelial cell markers: cytokeratins (CK) or epithelial cell
adhesion molecule (EpCAM). CK are commonly used for
detection of disseminated tumour cells in blood and bone
marrow samples (9, 11, 14, 15-19, 23, 24). A combination of
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sorting of CD45+ cells from blood samples, followed by
detection of CK+ cells among CD45– cells or CK18- and
CK20-mRNA were used for the detection of cancer cells in
patients with gastric cancer prior to surgery (22, 24, 25).
Although, both flow cytometry and immunofluorescence
used for the detection of cancer cells are sensitive, false-
positive or -negative results can still occur. Non-tumour cells
expressing CK in the blood and low and/or heterogeneous
expression of CK in cancer cells are the most frequent
causes of false-positive or -negative results (14). 
In this study, circulating tumour cells (CK+) in the blood
were detected among sorted CD45– cells of patients with
different clinical stages of gastric cancer before surgery was
carried out. Additional peripheral blood samples taken
immediately after the surgery and from the vessels draining
the tumour site during operation were studied. Analysis of
the survival of patients in relation to the presence of
disseminated cancer cells was also undertaken.
Patients and Methods
Patients. The analysis included 57 patients who underwent surgery
for gastric cancer between 1997 and 1999 at the First Department
of Surgery, Jagiellonian University Medical College. Patients who
died within 60 days after surgery and patients with secondary
malignancies were excluded from the study. TNM/UICC
classification criteria according to WHO (1997) were used for
tumor staging (7) while histopathological type (intestinal and
diffuse) of tumours was classified according to Lauren (8). The
intestinal type tumors located in the lower third of the stomach
qualified for subtotal gastrectomy, while diffuse type cancers
qualified for total gastrectomy. The extent of lymphadenectomy
was at the discretion of the surgeon, however the majority of
patients underwent D2 lymph node dissection. Provision of
postoperative chemotherapy was dependent on the stage of disease.
Follow-up clinical examinations were performed every 3-6 months.
Analysis of survival was based on mortality data from the Census
Registry Office. Since it was not possible to obtain records of
cancer - related death for all patients, the data presented is based
on overall survival rates. The study was approved by the Ethical
Committee of the Jagiellonian University. Written informed
consent was obtained from all patients.
Detection of tumour cells. Peripheral blood was collected in EDTA-
containing plastic tubes prior to surgery (sample A), immediately
after surgery (sample B) and from the vessels draining the tumour
site during surgery (sample C). 
The pellet of the cells from blood samples were incubated with
lysing buffer (Becton-Dickinson, Biosciences, Immunocytometry
Systems, San Jose CA, USA) (10 x volume, 10 min, repeated 3-4
times) to remove the erythrocytes. Leukocytes were washed in
phosphate buffered saline (PBS) and adjusted to the concentration
of 10x106 cells/ml after washing with PBS. Cells were stained with
anti-CD45 PE (phycoerythrin) conjugated monoclonal antibody
(mAb, DAKO, Glostrup, Denmark) and sorted into CD45+ and
CD45– populations using flow cytometry (FACS Vantage SE, BD
Biosciences, Immunocytometry Systems, San Jose CA, USA),
equipped with TurboSort option and Aerosol Protection System
(Flexoduct International ApS, Greve, Denmark). The ion laser
Innova Enterprise II (Coherent, Santa Clara, CA, USA) operating
at 488 nm was used as a light source. Sorting was performed using
a 70 mm nozzle tip with a drop drive frequency of 65 kHz, 1.5 drop
envelopes and "normal-R" sort mode. Sorted CD45– cells were
collected into water-cooled (constant temperature circulator,
Neslab Instruments, Portsmouth, NH, USA) polystyrene Falcon
2057 tubes (BD Biosciences, Two Oak Park, Bedford MA, USA)
precoated with foetal calf serum to avoid plastic charging and cell
attachment to the wall. The CD45– sorted cells (1x106 cells/ml)
were used for making the smears (22, 24, 25). 
The slides were dried, fixed with an ethanol and acetone mixture
(1:1 vol) then stained with A45-B/B3 mAb (Micromet GmbH,
Germany), which recognizes common epitopes of CK8, CK18 and
CK19, (5 Ìg/ml) for 30 min, washed and then stained with goat
anti-mouse IgG antibody labelled with fluorescein - FITC (working
dilution 1:50) for 30 min. After washing with PBS, cover slides were
put on and the slides were assayed within 2 days of staining. The
CK+ cells were identified by two independent investigators under
fluorescence microscopy (Olympus, Japan) and documented with
a DP10 camera (Olympus, Japan). The samples were regarded as
positive when at least 3 cells CK+ per slide were found.
Accordingly, patients were classified into CK+ and CK– groups.
Statistical analysis. The differences between groups of patients with
or without CK+ cells were analysed using Fisher’s exact test and
the Mann-Whitney U-test. Survival data were analysed according
to the Kaplan-Meier method and the log-rank test was used for
assessment of the differences. P<0.05 was considered statistically
significant. Statistical analysis was performed using Statistica 6.0
(StatSoft Inc., Tulsa, OK, USA) software package.
Results
Occurrence of tumour cells in the blood of gastric cancer
patients. A total of 57 patients with different clinical stages
(I-IV) of gastric cancer were evaluated. The CK+ cells
detected in blood were considered as presumptive tumour
cells. Tumour cells were detected in 31 patients (54.4%).
Table I present the comparision of clinicopathological
characteristics of patients with and without circulating
tumour cells in the peripheral blood before surgery.
Although the percentage of male patients predominated in
both groups, the male/female ratio was similar. In both
groups, diffuse type cancer according to Lauren’s
classification slightly predominated over the intestinal type.
There were no major differences in the distribution of
clinical stages between the groups. In 43 (75.4%) of all
cases, lesions infiltrated gastric serosa and/or the
surrounding organs (T3-4), and in the remaining 14 patients
(24.5%) tumour infiltration was limited to the mucosal,
submucosal or muscular layer (T1-2). Lymph node and
distant metastases were equally distributed among both
groups. Total gastrectomy was performed in 33 patients
(57.89%) whereas 23 patients (40.35%), underwent subtotal
gastrectomy, with a similar proportion in both groups.
Moreover, there were no differences in the percentage of
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patients who underwent neo-adjuvant or postoperative
chemotherapy. Therefore these two groups did not show
any significant differences in the parameters defined.
There was no clear association of the presence of CK+
cells with TNM stage, although the highest detection rate
was noted in stage I (Figure 1). The analysis of peripheral
blood samples prior to surgery (A), immediately after
surgery (B) and tumour-draining blood (C) showed a higher
frequency of CK+ cells in sample A: 54.4% as compared to
sample B: 21.1% and sample C: 26.8% (Figure 2). An
analysis of paired 26 patients in whom all blood samples
were obtained and who had tumour cells in the blood prior
to surgery (sample A - 100%) was performed (Figure 3, left
panel). The data show that immediately after gastrectomy,
tumour cells were detected in only 42.3% of patients.
Hence, it represents a substantial drop in the blood
positivity after surgery. Tumour cells were present in all
blood samples at 23.7%, A and B samples at 19.2%, and A
and C samples at 26.9% of patients (Figure 3, right panel).
Survival of patients with and without circulating tumour cells.
Analysis of overall survival at 5-years showed no differences
between patients with or without circulating tumour cells
(Figure 4). In patients with stage IV disease, the presence
of circulating tumour cells was associated with a shorter
survival, but the difference was not significant (Figure 5).
Since other prognostic variables among these two groups
were comparable (Table I), it seems to suggest that the
presence of cancer cells in the blood before surgery is of no
independent prognostic value in this limited group of
patients with gastric cancer.
Discussion
The presence of tumour cells in the peripheral blood of
patients with gastric cancer was assayed before and after
surgery, and in the tumour-draining blood. Tumour cells
were detected more often in the blood prior to surgery than
in the remaining blood samples. Paradoxically, the highest
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Table I. Clinicopathological characteristics of patients with or without
circulating tumour cells.




male 24 (77.42%) 20 (76.92%)
female 7 (22.58%) 6 (23.08%)
Stage
IA 3 (9.68%) 3 (11.54%)
IB 6 (19.35%) 1 (3.85%)
II 2 (6.45%) 6 (23.08%) 
IIIA 3 (9.68%) 2 (7.69%)
IIIB 0 (0.00%) 1 (3.85%)
IV 17 (54.84%) 13 (50.00%)
Depth of infiltration
T1-2 9 (29.03%) 5 (19.23%)
T3-4 22 (70.97%) 21 (80.77%)
Histolopatological type of the tumour
intestinal 13 (41.93%) 7 (26.92%)
diffuse 18 (58.06%) 19 (73.08%) 
LN status
N0 12 (38.71%) 9 (34.61%)
N1-3 19 (61.29%) 17 (65.38%)
Distant metastases
M0 28 (90.32%) 22 (84.61%)
M1 3 (9.68%) 4 (15.38%)
Surgical procedure
total gastectomy 19 (61.29%) 14 (53.86%)
subtotal gastrectomy 11 (35.48%) 12 (46.15%)
Postoperative chemotherapy 11 (35.48%) 12 (46.15%)
There were no significant differences between CK+ and CK– groups
for any parameter.
Figure 1. The occurrence of tumour (CK+) cells in the peripheral blood of
patients with gastric cancer prior to surgery.
Figure 2. The frequency of tumour cells detection in the peripheral blood
before surgery (sample A), immediately after surgery (sample B) and from
tumour-draining blood (sample C). 
frequency of cancer cells in the blood was seen in stage I
patients, but overall there was no clear relationship between
their occurrence and the stage of disease. The lower
frequency of circulating cancer cells in samples taken
immediately after surgery suggested that surgery of the
primary tumour did not cause the release of cancer cells
into the blood. This is in contrast to other studies
demonstrating the presence of CEA-mRNA positive cells in
the blood of 46% gastric cancer patients after, but not
before, gastrectomy, which disappeared within 2
postoperative days (19). The increase of cancer cells output
from the primary tumour during surgery depends on the
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Figure 3. The subanalysis of the frequency of circulating tumour cells in paired blood samples of 26 patients. Only patients with the presence of CK+ cells
in sample A were included.
Figure 4. The overall 5-year survival curve of gastric cancer patients with
(n=31) or without (n=26) the presence of tumour cells in the blood. 
Figure 5. The overall 5-year survival of stage IV gastric cancer patients
with (n=17) or without (n=13) circulating tumour cells.
performance of surgery and the tumour vascular network
which, if at a high density, may facilitate tumour cell
migration via the blood. Surprisingly, in our studies tumour
cells in the tumour draining blood were less frequent than in
peripheral blood suggesting that the former may also have
arrived via the lymphatic circulation. They were detected in
27% of patients which is similar to the 44% detection rate
of CEA/CK20-mRNA positive cells in mesenteric blood of
patients with colorectal carcinoma (26).
The detection of tumour cells in the blood is difficult and
techniques and detection rates vary considerably (13, 14, 17,
19, 21, 23, 26-28). To date only two studies in gastric cancer
were reported. One included 30 patients and CK20-mRNA
tumour cells in the blood prior to surgery were detected in
17% of patients (27), while in the other, no CEA-mRNA
positive cells were found in 59 patients (19). The frequency
of gastric cancer cell detection in the present study was much
higher, but the sorting of the CD45– population may have
influenced these results as it leads to "concentration" of
tumour cells. Furthermore, the use of mAb against several
types of cytokeratins may be an important factor in this
procedure. However, in patients with colorectal cancer, the
use of CK20-mRNA led to a detection rate of 17-48% (27,
28). Although our method is sensitive, allowing the detection
of 1 tumour cell per 106 - 107 leukocytes (22, 25), it should
be noted that occasionally the population of sorted CD45–
cells may contain CK+ epithelial cells which leads to false-
positive results (14). This is also true for the CK19/CK20-
mRNA used for cancer cell detection as it was also found to
be present in the blood of 10-20% patients with benign bowel
disease (23). However, our unpublished observations indicate
that isolated CK+ cells contain MAGE 1 or 2-mRNA. The
false-negative results may arise from cancer cell loss during
the separation procedures, down-regulation of CK expression
by tumour cells, or its heterogeneous expression on tumour
cells at different sites in a single patient (14, 15). 
The presence of disseminated tumour cells in the blood,
bone marrow or peritoneum was found to be an adverse
prognostic factor in gastric cancer (6, 10, 12, 14, 18), but the
opposite results were also noted (19). In the present study
no clear correlation between the presence of CK+ cells in
the blood and the 5-year survival of patients was observed.
There are only two reports on the prognostic relevance of
the presence of circulating cancer cells in patients with
gastric cancer. One included 30 patients and showed that
the presence of CK20-mRNA was associated with shortened
survival (14). The other based on 59 patients, showed no
difference in the survival between CEA-mRNA positive and
negative patients (19), which is in agreement with our data.
These apparent discrepancies are not surprising as tumour
cells in the blood are in a transitory stage during their
migration to different organs and tissues. In the early stages
of disease, the anti-cancer activity of the host may eliminate
cancer cells and they can also undergo spontaneous
apoptosis (29). Alternatively, cancer cells expressing some
chemokine receptors may migrate to the bone marrow
where they can remain for a long time in a dormant state
(14, 15, 30). This is associated with the expression of
CXCR4 which plays a role in tumour cells homing to bone
marrow (31).
Conclusion
The mere presence of circulating cancer cells may not
necessarily be associated with the metastatic spread of
disease. The present study seems to support this view. We
are undertaking a study with a larger group of patients and
multiple markers of tumour cells to substantiate these
findings. 
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